Search
bosutinib (Bosulif, SKI-606)
Indications:
- Philadelphia chromosome positive chronic myelogenous leukemia (CML)
- not recommended (NICE), see NGC guideline
- autosomal dominant polycystic kidney disease (ADPKD) [4]
- may slow cyst growth (66%)
Dosage:
- 500 mg PO QD with food until disease progression or patient intolerance
- 200 mg/day (ADPKD)
Tabs: 100 mg, 500 mg
Adverse effects:
- common (> 20%)
- diarrhea, nausea, thrombocytopenia, vomiting, abdominal pain, rash, anemia, pyrexia, and fatigue
- serious adverse reactions
- anaphylactic shock, myelosuppression, hepatoxicity
Mechanism of action:
- tyrosine kinase inhibitor
- inhibits Src, Abl
Interactions
drug adverse effects of tyrosine kinase inhibitor(s)
General
antineoplastic tyrosine kinase inhibitor
Database Correlations
PUBCHEM correlations
References
- Wikipedia: Bosutinib
http://en.wikipedia.org/wiki/Bosutinib
- FDA Approval for Bosutinib, September 4, 2012
National Cancer Institute
http://www.cancer.gov/cancertopics/druginfo/fda-bosutinib
- Cortes JE et al
Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase
Chronic Myeloid Leukemia: Results From the BELA Trial.
J Clin Oncol. 2012 Oct 1;30(28):3486-92. Epub 2012 Sep 4.
PMID: 22949154
- Minerd J
Cancer Drug May Help in ADPKD.
Bosutinib slowed kidney enlargement in phase II study.
MedPage Today. August 24, 2017
https://www.medpagetoday.com/Nephrology/GeneralNephrology/67482
- Tesar V, Ciechanowski K, Pei Y al
Bosutinib versus placebo for autosomal dominant polycystic
kidney disease
J Am Soc Nephrol. 2017 Aug 24. pii: ASN.2016111232.
PMID: 28838955